NFS 10
Alternative Names: NFS-10; rAAV-anti-VEGFLatest Information Update: 28 Mar 2025
At a glance
- Originator Neurophth Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Macular degeneration
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Macular-degeneration in China (Intravitreous, Injection)
- 04 Feb 2021 NFS 10 is available for licensing as of 04 Feb 2021. https://www.neurophth.com/en/Business.html (Neurophth Therapeutics Pipeline, February 2021)
- 04 Feb 2021 Preclinical trials in Macular degeneration in China (Intravitreous), prior to February 2021 (Neurophth Therapeutics Pipeline, February 2021)